Atazanavir
HIV-1 protease inhibitor / An azapeptide-based inhibitor of HIV protease (Ki = 2.66 nM).1 Inhibits SARS-CoV-2 main protease (Ki = 703 nM), but not papain-like protease (Ki = 9.87 µM).2 Blocks SARS-CoV-2 replication and IL-6 / TNFα production in vitro.3 Also inhibits the liver enzyme UDP-glucuronyltransferase 1A1 (UGT1A1), IC50 = 160 nM for recombinant UGT1A1.4
Biochemicals & reagents
198904-31-3
BMS 232632; CGP 73547; Latazanavir
1 Robinson et al. (2000), BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents; Antimicrob. Agents Chemother. 44 2093 2 Chaves et al. (2021), Atazanavir is a Competitive Inhibitor of SARS-CoV-2 Mpro, Impairing Variants Replication In Vitro and In Vivo; Pharmaceuticals (Basel) 15 21 3 Fintelman-Rodrigues et al. (2020), Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production; Antimicrob. Agents Chemother. 64 e00825 4 Mullapudi et al. (2021), UGT1A1 and UGT1A3 activity and inhibition in human liver and intestinal microsomes and a recombinant UGT system under similar assay conditions using selective substrates and inhibitors; Xenobiotica 51 1236
-20°C
DISEASE AREA: Infectious disease